{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=22", "query": { "condition": "Advanced Solid Neoplasm", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 3387, "total_pages": 339, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T08:28:13.293Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06716138", "title": "A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration" ], "interventions": [ { "name": "ANS03", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avistone Biotechnology Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2025-03-06", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-11-11T08:28:13.293Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06716138" }, { "nct_id": "NCT06725758", "title": "A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "ODM-212", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orion Corporation, Orion Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 315, "start_date": "2023-10-26", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-11-11T08:28:13.293Z", "location_count": 8, "location_summary": "Los Angeles, California • Orange, California • St Louis, Missouri + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06725758" }, { "nct_id": "NCT06782555", "title": "A Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Evofosfamide", "type": "DRUG" }, { "name": "Zalifrelimab", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGenesis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2025-01-08", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-11T08:28:13.293Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06782555" }, { "nct_id": "NCT07223047", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Malignancies", "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "BMS-986523", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2025-11-25", "completion_date": "2028-10-13", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-11-11T08:28:13.293Z", "location_count": 4, "location_summary": "Baltimore, Maryland • San Antonio, Texas • West Valley City, Utah + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223047" }, { "nct_id": "NCT06328738", "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2 Positive Solid Tumors", "HER2 Amplification", "Colorectal Cancer" ], "interventions": [ { "name": "ELVN-002", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enliven Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2024-05-30", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-11-11T08:28:13.293Z", "location_count": 3, "location_summary": "Plantation, Florida • St Louis, Missouri • Fairfax, Virginia", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06328738" }, { "nct_id": "NCT07650357", "title": "A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Pancreatic Carcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "CLSP-5282", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clasp Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2026-07", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-11-11T08:28:13.293Z", "location_count": 4, "location_summary": "Durham, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07650357" }, { "nct_id": "NCT00839631", "title": "Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "EC D-3263 HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dendreon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2009-03", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-05-02", "last_synced_at": "2026-11-11T08:28:13.293Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00839631" }, { "nct_id": "NCT06599502", "title": "A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours", "Non-Small Cell Lung Cancer (NSCLC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "AZD0022", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2024-10-18", "completion_date": "2026-01-29", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-11-11T08:28:13.293Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York • Fairfax, Virginia", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06599502" }, { "nct_id": "NCT04608045", "title": "Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "CPX-POM", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CicloMed LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2019-05-19", "completion_date": "2023-04-30", "has_results": true, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-11-11T08:28:13.293Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04608045" }, { "nct_id": "NCT05578872", "title": "A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin)", "Cutaneous Melanoma", "Adult Disease", "Advanced Solid Tumor", "Metastatic Melanoma" ], "interventions": [ { "name": "ANV419", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anaveon AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2022-12-16", "completion_date": "2024-08-01", "has_results": true, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-11-11T08:28:13.293Z", "location_count": 9, "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05578872" } ] }